Evaluation of the Efficacy and Tolerability of Detralex in Patients With Chronic Venous Edema in Real Clinical Practice

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

708 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-12-06

Study Completion Date

2019-06-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The VAP-PRO-C3 is a multicenter observational program, which is carried out in the frame of routine consultations and follow-up of patients. The program includes patients with chronic venous diseases (CVDs) of CEAP class C3. It is scheduled in Russia for 2018-2019. The program is expected to enroll 90 phlebologists from 60 cities of Russia. The planned number of patients is 900

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Related to the VOYAGER PAD Trial to Learn More About the Target Population for Xarelto in French Patients

NCT04824729

Peripheral Artery Disease

COMPLETED

PMCF of Rotarex®S & Aspirex®S Catheters in Treating Thrombotic Occlusion of Arteriovenous Graft

NCT05071872

Arteriovenous Graft Thrombosis

COMPLETED

Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment

NCT02539940

Critical Limb Ischemia Peripheral Artery Disease

COMPLETED

Availability of Venous Conduits in Patients With Varicose Veins for Arterial Bypass Surgery

NCT06332833

Varicose Veins Peripheral Arterial Disease

COMPLETED

Randomized Trial of IN.PACT Admiral® Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease

NCT01175850

Peripheral Arterial Disease (PAD)

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is aimed at evaluating the efficacy and safety of systemic pharmacotherapy (Detralex) as a part of combination treatment, and its influence on the general outcomes of treatment of patients with chronic venous edema (CEAP class C3) in real clinical practice.

Each investigator is planned to include in the program 10 patients fulfilling the inclusion criteria. The treatment will be carried out in accordance to the routine clinical practice, instructions for the medical use of drugs, and a specific clinical situation. To assess changes in edema, the method of truncated cones and duplex ultrasound scanning (DUS) will be used.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Venous Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years old or above
* Written informed consent
* Patient did not receive treatment with venoactive drugs within the past 4 weeks prior to the inclusion in the study
* Diagnosis of chronic venous disease of class C3 (CEAP)
* Decision of an attending physician to prescribe Detralex.

Exclusion Criteria

* Age below 18 years old
* Written informed consent is not obtained
* History of alcohol or drug abuse or use of narcotic drugs
* History of allergic reaction to diosmin or any other venoactive agent, or their intolerance
* History of allergic reaction to anesthetics and/or sclerosing agents
* Chronic venous disease of СЕАР class C0-С2 or class С4-С6
* Lymphatic edema of the lower extremities
* Secondary varicose veins, angiodysplasia, or neoplasia
* Arterial disease (ankle-brachial index \<0.9)
* Infection within the past 6 weeks
* Any of the following concomitant diseases, which can affect the results:

* Connective tissue disease (including rheumatoid arthritis), arthritis
* Heart failure
* Intermittent claudication (peripheral artery disease)
* Diseases of the bones or joints of the lower extremities
* Malignancy
* Treatment with drugs potentially causing leg edema (calcium channel blockers, hormonal drugs, NSAIDs, etc.)
* History of deep vein thrombosis (within the past year)
* History of superficial thrombophlebitis (within the past 3 months)
* Patient cannot walk (regardless of the cause)
* Obesity or body mass index \[BMI\] \>30 kg/m2 \[BMI = body mass (kg)/height (m)2\]
* Predictable poor adherence to treatment
* Participation of the patient in the intervention study within the previous 3 months
* For women: pregnancy or breastfeeding, the desire to become pregnant within at least 2 months after the study
* Patient cannot attend a follow-up visit
* Patients with a contraindication to diosmin-containing agents, including Detralex

Minimum Eligible Age

18 Years

Maximum Eligible Age

79 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No